A Study on Vonoprazan in the Real-world Clinical Practice in China
- Conditions
- Esophagitis Peptic
- Registration Number
- NCT04501627
- Lead Sponsor
- Takeda
- Brief Summary
The purpose of this study is to evaluate the safety of Vonoprazan by assessing all adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs) in routine clinical settings in China.
- Detailed Description
This is a prospective, non-interventional study in Chinese participants with RE who are receiving or will receive the standard treatment of vonoprazan. This study will assess the safety and effectiveness of vonoprazan in the real-world clinical practice.
The study will enroll approximately 3000 participants. The data will be collected through participants' medical records, self-reported questionnaires, and recorded information on symptom via diaries. All the participants will be assigned to a single observational cohort:
β’ Participants with RE
The multi-center trial will be conducted in China. The standard treatment will be of 4 weeks or it may reach up to 8 weeks if the dosing proves insufficient. All participants will be followed up for additional 2 weeks after the standard treatment. The overall duration of the study will be approximately 10 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
- Must be undergoing treatment with Vonoprazan.
- Must be at least 18 years old.
- Provide signed informed consent indicating that they (or a legally acceptable representative) have been informed of all pertinent aspects of the study and are willing to participate.
- Are currently enrolled in or plan to participate in any other clinical trials (that is interventional study).
- Are contraindicated for Vonoprazan according to Product Package Insert.
- With a known hepatic function impairment, including jaundice.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of Participants Reporting one or More ADRs Up to Week 10 ADRs refers to AE related to administered drug.
Percentage of Participants Reporting one or More SAEs Up to Week 10 Percentage of Participants Reporting one or More AEs Up to Week 10
- Secondary Outcome Measures
Name Time Method Percentage of Participants with Endoscopic Healing of Reflux Esophagitis (RE) During 4-week Treatment Baseline up to Week 4 Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification Grade O during the treatment phase. The definitions of each grade are: Grade O (No mucosal break), Grade A (Mucosal break less than \[\<\] 5 millimeter \[mm\]), Grade B (Mucosal break greater than or equal to \[\>=\] 5 mm), Grade C (Mucosal break continuous between two or more folds and \<75% of the esophageal circumference) and Grade D (Mucosal break \>=75 percent \[%\] of the esophageal circumference).
Percentage of Participants With Acid Regurgitation at Baseline Achieving Complete Acid Regurgitation Symptom Relief During the First Week of Treatment Baseline up to Week 1 The complete relief of acid regurgitation symptom is defined as no symptoms of acid regurgitation occurring on 7 consecutive days. Percentage of participants with complete relief during Week 1 will be reported. Reported data will be the percentage of participants, calculated by the (number of participants with complete acid regurgitation symptom relief) divided by (the total number of participants) \*100%.
Percentage of Participants With Night Time Acid Regurgitation Symptom at Baseline Achieving Complete Night Time Acid Regurgitation Symptom Relief During the First Week of Treatment Baseline up to Week 1 The complete relief of acid regurgitation symptoms durng night time is defined as no symptoms of acid regurgitation occurring on 7 consecutive nights. Percentage of participants with complete relief during Week 1 will be reported. Reported data will be the percentage of participants, calculated by the (number of participants with complete night time acid regurgitation symptom relief) divided by (the total number of participants) \*100%.
Percentage of Participants with Endoscopic Healing of RE During 8-week Treatment Baseline up to Week 8 Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification Grade O during the treatment phase. The definitions of each grade are: Grade O (No mucosal break), Grade A (Mucosal break \<5 mm), Grade B (Mucosal break \>=5 mm), Grade C (Mucosal break continuous between two or more folds and \<75% of the esophageal circumference) and Grade D (Mucosal break \>=75% of the esophageal circumference).
Percentage of Participants with Night Time Heartburn at Baseline Achieving Complete Night Time Heartburn Symptom Relief During the First Week of Treatment Baseline up to Week 1 The complete relief of night time heartburn symptoms is defined as no such symptom occurred on 7 consecutive nights. Percentage of participants with complete relief during Week 1 will be reported. Reported data will be the percentage of participants, calculated by the (number of participants with complete night time heartburn symptom relief) divided by (the total number of participants) \*100%.
Percentage of RE Participants Without Gastroesophageal Reflux Disease (GERD) Typical Symptoms Baseline and Week 4 The severity of participants' GERD symptoms based on the investigator's assessment among all participants will be evaluated at Baseline and Week 4. GERD symptoms will be assessed on a 5-point scale, wherein 1= no symptom, 2= mild, 3= moderate, 4= severe and 5= very severe. GERD symptoms include heartburn (HB), acid regurgitation (AR), dysphagia (dysp), belching (bch) and epigastric pain (EP). The participants without any GERD typical symptoms will be analyzed.
Percentage of Participants With Heartburn at Baseline Achieving Complete Heartburn Symptom Relief During the First Week of Treatment Baseline up to Week 1 The complete relief of heartburn symptom is defined as no such symptom occurred on 7 consecutive days. Percentage of participants with complete relief during Week 1 will be reported. Reported data will be the percentage of participants, calculated by the (number of participants with complete heartburn symptom relief) divided by (the total number of participants) \*100%.
Change from Baseline in Gastroesophageal Reflux Disease Questionnaire (GerdQ) Score at Week 4 Baseline up to Week 4 GerdQ is a self-completed participant questionnaire that is used to assess whether the following symptoms of RE are improved under treatment: heartburn, regurgitation, stomach pain, nausea, sleep disturbance and use of additional medication due to heartburn/regurgitation. Symptom frequency will be assessed for the week passed using following answers: 0 days, 1 day, 2-3 days, and 4-7 days. Each answer will be assigned a score from 0 to 3 (heartburn, regurgitation, sleep disturbance and use of additional medication due to heartburn/regurgitation) or from 3 to 0 (stomach pain, nausea). Total score will be calculated as a sum of 6 individual scores. GerdQ score was calculated as sum of these scores, giving a total score ranging from 0 to 18. When GerdQ \>=8, the participants could be symptom based diagnosed as GERD. Total score of 0 to 2 points= 0% likelihood of GERD; 3 to 7 points= 50% likelihood of GERD; 8 to 10 points= 79% likelihood of GERD; 11 to 18 points= 89% likelihood of GERD.
Trial Locations
- Locations (40)
Beijing Tsinghua Changgung Hospital
π¨π³Beijing, Beijing, China
Heilongjiang Provincial Hospital (Nanshang)
π¨π³Harbin, Heilongjiang, China
Wenzhou Central Hospital
π¨π³Wenzhou, Zhejiang, China
The Fourth Affiliated Hospital Zhejiang University School of Medicine
π¨π³Yiwu, Zhejiang, China
Henan Provincial Peoples Hospital
π¨π³Zhengzhou, Henan, China
Nanjing First Hospital
π¨π³Nanjing, Jiangsu, China
Beijing Hospital
π¨π³Beijing, Beijing, China
Peking Union Medical College Hospital
π¨π³Beijing, Beijing, China
Zhuhai People's Hospital
π¨π³Zhuhai, Guangdong, China
The Third Affiliated Hospital, Sun Yat-sen University
π¨π³Guangzhou, Guangdong, China
Yongchuan Hospital of Chongqing Medical University
π¨π³Yongchuan, Chongqing, China
Huazhong University of Science and Technology Union Shenzhen Hospital
π¨π³Shenzhen, Guangdong, China
Lanzhou University Second Hospital
π¨π³Lanzhou, Gansu, China
The Second Affiliated Hospital of Guangzhou Medical University
π¨π³Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
π¨π³Guangzhou, Guangdong, China
The First Affiliated Hospital of Sun Yat-sen University
π¨π³Guangzhou, Guangdong, China
Union Hospital, Tongji Medical College of Huazhong University of Science & Technology
π¨π³Wuhan, Hubei, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
π¨π³Wuhan, Hubei, China
The Affiliated Drum Tower Hospital of Nanjing University
π¨π³Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
π¨π³Nanjing, Jiangsu, China
Changshu No.2 People's Hospital
π¨π³Changshu, Jiangsu, China
Jiangxi Provincial People's Hospital
π¨π³Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
π¨π³Nanchang, Jiangxi, China
The First Hospital of Jilin University
π¨π³Changchun, Jilin, China
The First Hospital of China Medical University
π¨π³Shenyang, Liaoning, China
Qilu Hospital of Shandong University
π¨π³Jinan, Shandong, China
Shandong Provincial Hospital
π¨π³Jinan, Shandong, China
Qilu Hospital of Shandong University (Qingdao)
π¨π³Qingdao, Shandong, China
Weifang Peoples Hospital
π¨π³Weifang, Shandong, China
Yantai Affiliated Hospital of Binzhou Medical College
π¨π³Yantai, Shandong, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
π¨π³Shanghai, Shanghai, China
The Affiliated Hospital of Hangzhou Normal University
π¨π³Hangzhou, Zhejiang, China
Chengdu Third People's Hospital
π¨π³Chengdu, Sichuan, China
West China Hospital, Sichuan University
π¨π³Chengdu, Sichuan, China
General Hospital of Tianjin
π¨π³Tianjing, Tianjin, China
Zhejiang Provincial People's Hospital
π¨π³Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
π¨π³Hangzhou, Zhejiang, China
The Affiliated Hospital of Medical School of Ningbo University
π¨π³Ningbo, Zhejiang, China
The Second Affiliated Hospital of Wenzhou Medical College
π¨π³Wenzhou, Zhejiang, China
Jiangsu Province Hospital
π¨π³Nanjing, Jiangsu, China